// App-Quantinova.ai

CTIM-24 : NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA

Researchers

Presenter

  • Hao-Wen Sim

Principal Investigators

  • Elizabeth Barnes

  • Kerrie McDonald

  • Sonia Yip

  • Roel Verhaak

  • Amy Heimberger

  • Merryn Hall

  • Matthew Wong

  • Ross Jennens

  • David Ashley

  • Mark Rosenthal

  • Elizabeth Hovey

  • Benjamin Ellingson

  • Annette Tognela

  • Hui Gan

  • Michael Back

  • Eng-Siew Koh

  • Anne Long

  • Katharine Cuff

  • Stephen Begbie

  • Craig Gedye

  • Anna Mislang

  • Hien Le

  • Margaret Johnson

  • Benjamin Kong

  • John Simes

  • Mustafa Khasraw

Medical Centers

  • The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, USA

  • Epworth Healthcare, Melbourne, Australia

  • The Jackson Laboratory, Farmington, USA

  • UCLA Brain Tumor Imaging Laboratory, Los Angeles, CA, USA

  • Liverpool Hospital & South Western Sydney Clinical Campus, University of New South Wales, Sydney, New South Wales, Australia

  • Royal Adelaide Hospital, Adelaide, Australia

  • Port Macquarie Hospital, Port Macquarie, Australia

  • Prince of Wales Hospital, Sydney, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Northwestern University, Chicago, USA

  • Sir Charles Gairdner Hospital, Perth, Australia

  • Flinders Medical Centre, Adelaide, Australia

  • Campbelltown Hospital, Sydney, Australia

  • Royal North Shore Hospital, Sydney, New South Wales, Australia

  • Gosford Hospital, Gosford, Australia

  • Department of Medical Oncology, Calvary Mater Hospital, Waratah, NSW, Australia

  • University of New South Wales, Sydney, Australia

  • Princess Alexandra Hospital, Brisbane, Australia

  • PETER MACCALLUM CANCER CENTRE, MELBOURNE, Australia.

  • Royal Brisbane and Women’s Hospital, University of Queensland, Brisbane, Australia

  • Olivia Newton John Cancer Research Institute, Melbourne, Australia

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • O-6-methylguanine DNA methyltransferase

Drug/Treatment

  • Temozolomide

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04195139

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved